drugset / Trial / NCT06121375

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

NCT06121375

Phase 2/3 Terminated 28 enrolled Intercept Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy, safety and tolerability, as well as PK/PD of OCA in eligible pediatric participants with biliary atresia with successful hepatoportoenterostomy (HPE, also known as a Kasai portoenterostomy). The double-blind period comprises of 2 phases: dose titration phase and age expansion treatment phase.

Timeline

Start
2024-09-02
Primary completion
2025-10-21
Completion
2025-10-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Obeticholic Acid Small molecule Oral

Indications